Neoplasms

All Conditions

Nervous System Diseases

Gland and Hormone Related Diseases

Symptoms and General Pathology

Rare Diseases

Adenoma

Pituitary Diseases

Recurrence

Central Nervous System Neoplasms

Nervous System Neoplasms

Pituitary Neoplasms

Prolactinoma

Adenoma, Basophil

Adenoma, Chromophobe

Adenoma, Acidophil

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

Endocrine Gland Neoplasms

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Temozolomide

Antineoplastic Agents, Alkylating

Alkylating Agents

temozolomide

DNA methylation analysis

microarray analysis

protein expression analysis

proteomic profiling

laboratory biomarker analysis

Anthony Heaney, MD

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with invasive pituitary tumors.

OBJECTIVES:

Primary

* To assess the effect of temozolomide on pituitary tumor growth in patients with invasive pituitary tumors.
* To assess the effect of temozolomide on pituitary tumor response and the duration of tumor response in these patients.

Secondary

* To assess the effect of temozolomide on pituitary tumor hormone secretion in these patients.
* To assess the effect of temozolomide on other aspects of pituitary function in these patients.
* To assess the overall safety and tolerability of temozolomide in these patients.
* To assess the overall quality of life of patients treated with temozolomide.

OUTLINE: This is a multicenter study.

Patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of 12 courses, patients achieving a complete or partial tumor response may continue to receive temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity.

Tumor tissue samples are collected periodically to assess methylation status of the methyl-guanine methyl-transferase promoter (MGMT) gene and to quantitate immunocytochemical expression of the tumor suppressor proteins p53, p16, and p27. Tissue samples are also analyzed by microarray and proteomics to determine a genetic "signature" of invasive vs non-invasive pituitary tumors and to determine if this signature correlates with response to temozolomide. Blood samples are also periodically for biomarker laboratory studies.

Patients complete a quality of life questionnaire periodically.

After completion of study therapy, patients are followed for 28 days.

Temozolomide in Treating Patients With Invasive Pituitary Tumors

An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Temozolomide in Treating Patients With Invasive Pituitary Tumors	NCT00601289	Brain and Centr...	temozolomide DNA methylation... microarray anal... protein express... proteomic profi... laboratory biom...	18 Years - 75 Years	Jonsson Comprehensive Cancer Center
Temozolomide in Treating Patients With Invasive Pituitary Tumors	NCT00601289	Brain and Centr...	temozolomide DNA methylation... microarray anal... protein express... proteomic profi... laboratory biom...	18 Years - 75 Years	Jonsson Comprehensive Cancer Center

Spots Global Cancer Trial Database for pituitary eosinophilic adenoma